Tirofiban
Tirofiban is a pharmaceutical drug with 37 clinical trials. Currently 7 active trials ongoing. Historical success rate of 78.9%.
Success Metrics
Based on 15 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
4
Mid Stage
27
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
78.9%
15 of 19 finished
21.1%
4 ended early
7
trials recruiting
37
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion
Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Tirofiban After Successful MT Recanalization in AIS
Clinical Trials (37)
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion
Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Tirofiban After Successful MT Recanalization in AIS
ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion
HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)
Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke
Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke
Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke
Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair
Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke
Intravenous Tirofiban After Delayed Thrombolysis in Stroke
Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4)
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
Reduction of Microembolism After the Intervention Surgery of Intracranial Aneurysms by Administration of Tirofiban
Tirofiban for Patients Treated With Alteplase
Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.
Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 37